Europe - BIT:1MRKX - US58933Y1055 - Common Stock
The current stock price of 1MRKX.MI is 79.4 EUR. In the past month the price increased by 14.41%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 11.84 | 219.12B | ||
| SNW.DE | SANOFI | 11.89 | 220.16B | ||
| MRK.DE | MERCK KGAA | 13.95 | 51.63B | ||
| UCB.BR | UCB SA | 34.1 | 42.59B | ||
| 1BAYN.MI | BAYER AG-REG | 5.81 | 28.59B | ||
| BAYN.DE | BAYER AG-REG | 5.89 | 28.45B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 26.4 | 10.87B | ||
| IPN.PA | IPSEN | 12.66 | 10.90B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 94.52 | 8.75B | ||
| VIRP.PA | VIRBAC SA | 20.56 | 2.99B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 16.83 | 1.80B | ||
| MEDCL.PA | MEDINCELL SA | N/A | 1.01B |
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
MERCK & CO. INC.
126 East Lincoln Avenue, P.O. Box 2000
Rahway NEW JERSEY US
Employees: 75000
Phone: 19087404000
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
The current stock price of 1MRKX.MI is 79.4 EUR. The price increased by 6.29% in the last trading session.
MERCK & CO. INC. (1MRKX.MI) has a dividend yield of 3.78%. The yearly dividend amount is currently 2.68.
1MRKX.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
MERCK & CO. INC. (1MRKX.MI) operates in the Health Care sector and the Pharmaceuticals industry.
MERCK & CO. INC. (1MRKX.MI) currently has 75000 employees.
MERCK & CO. INC. (1MRKX.MI) has a market capitalization of 198.32B EUR. This makes 1MRKX.MI a Large Cap stock.
ChartMill assigns a technical rating of 4 / 10 to 1MRKX.MI.
ChartMill assigns a fundamental rating of 7 / 10 to 1MRKX.MI. While 1MRKX.MI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months 1MRKX.MI reported a non-GAAP Earnings per Share(EPS) of 7.61. The EPS increased by 48.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.79% | ||
| ROA | 13.96% | ||
| ROE | 33.49% | ||
| Debt/Equity | 0.69 |
33 analysts have analysed 1MRKX.MI and the average price target is 87.64 EUR. This implies a price increase of 10.38% is expected in the next year compared to the current price of 79.4.
For the next year, analysts expect an EPS growth of 18.21% and a revenue growth 1.08% for 1MRKX.MI